Milton Ault III Sells 36,777 Shares of Alzamend Neuro (NASDAQ:ALZN) Stock

Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Milton Ault III sold 36,777 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $2.35, for a total transaction of $86,425.95. Following the completion of the sale, the director owned 94,849 shares of the company’s stock, valued at $222,895.15. This trade represents a 27.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Alzamend Neuro Stock Performance

Shares of ALZN opened at $2.53 on Friday. Alzamend Neuro, Inc. has a one year low of $2.06 and a one year high of $17.10. The company has a 50-day simple moving average of $2.40 and a two-hundred day simple moving average of $4.08.

Institutional Investors Weigh In On Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Citadel Advisors LLC bought a new position in Alzamend Neuro, Inc. (NASDAQ:ALZN) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned 0.56% of Alzamend Neuro at the end of the most recent quarter. 49.61% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have commented on the stock. Wall Street Zen lowered shares of Alzamend Neuro from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Weiss Ratings reiterated a “sell (e)” rating on shares of Alzamend Neuro in a report on Saturday, September 27th. Finally, Ascendiant Capital Markets lowered their target price on shares of Alzamend Neuro from $45.00 to $42.00 and set a “buy” rating for the company in a report on Thursday, September 25th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $42.00.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.